PharmaCyte Biotech Secures $7 Million in Funding Through Securities Purchase Agreement

Pharmacyte Biotech Signed a Securities Purchase Agreement with Existing Investors 

Announcement

Pharmacyte Biotech Inc. has signed a securities purchase agreement worth $7.0 million under financial terms with existing investors, engaging the sale of 7,000 shares of its newly positioned Series C convertible preferred stock. The stated value of a preferred share is $1,000 per share, convertible into an estimated 7,000,000 shares of its unregistered common stock purchase warrants and common stock to purchase around an aggregate of 7,000,000 shares of its common stock in a private placement. The private placement is expected to close by August 19, 2025, entitled to the satisfaction of customary closing conditions. GP Nurmenkari Inc. will be the sole placement agent for the private placement throughout the agreement.

In Detail About the Agreement

The preferred stock shares consist of a conversion price of $1.00 per share of common stock and accumulate a 7.0% quarterly dividend, which will be payable in cash. The warrants have a strike price of $1.00 per common share and are exercisable quickly, also for a period of five years from the date of issuance. The securities in the private placement ere provided and sold in transactions exempt from the needed registration of the securities act of 1933 under the securities act, the under the exemption for transactions by a receiver not engages in any public offering under section 4(a)(2) of the securities act and rule 506 of regulation D of the securities act and in connection on alike exemptions according to the applicable state laws.

Respectively to the shares of common stock receivable on strike or conversion of the warrants and preferred stock provided and sold in the private placement might not be available or sellable in the United States, excluding under an official registration statement or an applicable exemption from the needed registration of the related applicable state securities laws and the Securities Act. The company is ready to file a registration statement with the SEC registering the resale of the common stock shares receivable on conversion of the stock of the warrant and preferred stock received in reliance on the private placement.

Views and Statements from the Company Leaders

Interim chief executive officer of Pharmacyte, Josh Silverman, said, “This financing, priced at a premium to our company’s current market price and incorporated by our existing investors, shows a robust confidence in Pharmacyte’s future. This sensibly powers up our balance sheet and gives us a chance to improve shareholder value, and allows us to initiate strategic options that we know can leverage long-term returns for our stockholders.”